This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.
Clinical trial NCT00720603 · NO_LONGER_AVAILABLE
Trial details
- NCT number
- NCT00720603
- Sponsor
- Genzyme, a Sanofi Company
- Status
- NO_LONGER_AVAILABLE
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.